U.S. FDA Action Drives Ranbaxy Into Red; Company May Buyout Manufacturing Sites To Recover Lost Ground
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's largest drug maker Ranbaxy suffered heavy losses during its third quarter primarily due to U.S. FDA action in September that clamped an import ban on over 30 of its products
You may also be interested in...
U.S. FDA To Open India Office In December
NEW DELHI - U.S. FDA plans to step up scrutiny of drugs and food made in India for the U.S. market by setting up offices next month in the country after establishing three branches in China, according to U.S. officials
U.S. FDA To Open India Office In December
NEW DELHI - U.S. FDA plans to step up scrutiny of drugs and food made in India for the U.S. market by setting up offices next month in the country after establishing three branches in China, according to U.S. officials
After Ranbaxy, U.S. FDA Hauls Up Caraco Pharma for QC Issues; May Withhold Future Drug Approvals
MUMBAI - U.S. FDA issued a warning letter to Caraco Pharmaceuticals, a subsidiary of India's Sun Pharmaceuticals, after the drug regulator found quality control lapses at its Detroit facilities, Curaco announced Nov. 3. U.S. FDA said the QC lapses conflicted with the company's standard operating procedures